1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Cancer Supportive Care Products Market: Lung Cancer Segment Projected to Remain Dominant over the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016-2021

Cancer Supportive Care Products Market: Lung Cancer Segment Projected to Remain Dominant over the Forecast Period: Global Industry Analysis and Opportunity Assessment 2016-2021

  • December 2016
  • 212 pages
  • ID: 4665955
  • Format: PDF
  • Future Market Insight Global & Consulting Pvt Ltd
Up to $2000 off Until May 31st 2020

Summary

Table of Contents

With growing prevalence of cancer, the demand for cancer treatments, such as chemotherapy has also been consistently on the rise since the past decade.

However, radiation therapy brings with it a host of side effects that are challenging for cancer patients to face while they undergo the course of treatment. While the cancer treatment realm is tremendously progressing, the incidences of side effects are increasing as well, which are addressed by cancer supportive care. The advent of technology in cancer supportive care has enabled to treat different signs and symptoms following the chemotherapy procedure, in addition to chemotherapy-induced vomiting, nausea, neutropenia, and anemia.

The global market for cancer supportive care products is currently thriving at a sound pace and is anticipated to see steady growth over the next few years. In 2016, the global cancer supportive care products market will possibly attain a value of over US$ 25.0 Bn, which may ramp up by 2021 end to US$ 29.87 Bn. Burgeoning need for effective supportive care products will continue to drive the market during 2016-2021.

Prominence of Cancer Incidences Spurs Adoption of Supportive Care

Pronounced incidences of different types of cancers will remain a primary factor driving the demand for quality supportive care. In addition, higher effectiveness of available anti-cancer drugs and a wide range of side-effects of various cancer treatments collectively support the market for cancer supportive care products on a global basis. The recent past has been observing increasing adoption of cancer supportive care drugs in order to deal with adverse effects of anti-cancer drugs. This will continue to provide a strong impetus to the demand for cancer supportive care products.

Increasing Availability of Supportive Care Products and Rising Healthcare Spending Favour Market Growth

Increasing awareness about the availability of supportive care products is expected to play a key role in promoting cancer supportive care products, especially in developing countries. Moreover, several governments have been proactively amplifying their healthcare expenditure, which is another driver the market growth. Consistent R&D activities related to cancer treatment and cancer supportive care are also foreseen to collectively fuel the market growth over the next few years.

New Product Launches Persist to Fuel Global Demand

Manufacturers are constantly focusing on developing innovative drugs and other supportive care products, such as vaccines; over 20 molecular entities have been introduced to the market recently with an aim to implement an additional, more effective therapy or a combination therapy. This is identified as a major booster to the market growth for the forecast period, 2016-2021.

Chemotherapy-induced Neutropenia Incidences Push Demand for Erythropoietin Stimulating Agents

The global cancer supportive care products market is segmented on the basis of several classes. Erythropoietin stimulating agents segment is predicted to represent the largest market share of over 26% by 2021 end. This growth is attributed to increasing prevalence of chemotherapy-induced neutropenia. Granulocyte colony-stimulating factors are expected to maintain the second largest segment, expanding at a CAGR of 4.2% over 2016-2021.

Lung Cancer Remains Leader in Terms of Disease Condition

On the basis of disease indication, there are nine segments, including lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukemia, ovarian cancer, melanoma, and others. Lung cancer segment is projected to remain dominant over the forecast period with maximum market value share by 2021 end. However, breast cancer segment will witness a higher CAGR during 2016-2021.

APAC Projected for the Strongest Growth Rate, Followed by North America

By regional analysis, North America is foreseen to witness robust growth at a CAGR of 4.7% over 2016-2021, led by the U.S. Healthcare spending of the U.S. is estimated to rake in at an average rate of 5% over the next few years. This will be a strong factor bolstering the existing expenditure of cancer-inflicted patients across the country. Europe, the second most attractive market, will possibly capture around 22% share of the global market by 2021 end. Asia Pacific is likely to witness the highest CAGR, attributed to improving healthcare infrastructure and spending. The market in Latin America will gain a slight uptick, attributed to stable growth of the cancer supportive care products market in Brazil. MEA will also exhibit improved growth over the forecast period.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off

($5000)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on